People · Operator

Jeffrey Blair

Named in public records as an officer, director or promoter · active 2018–2024 · Biotechnology, Other Health Care

2
Companies
2
Filings
$12.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Euphrates Vascular, Inc.BiotechnologySeries A$9.7M$322.2M2018
Ichor Vascular Inc.Other Health CareSeed$3.1M$15.7M2024
Operator network

Jeffrey Blair at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Robert Mitchell · 9 companies · 1 sharedRobert MitchellSean Morris · 7 companies · 1 sharedSean MorrisERIC MOESSINGER · 6 companies · 1 sharedERIC MOESSINGERTHOMAS HILLMAN · 3 companies · 1 sharedTHOMAS HILLMANMartin Omid Akhavan · 2 companies · 1 sharedMartin Omid Akhav…Cathy Omid Matthes · 1 companies · 1 sharedCathy Omid MatthesTim Blair · 1 companies · 1 sharedTim BlairTROY LONG · 2 companies · 2 sharedTROY LONGMark Peterson · 5 companies · 1 sharedMark PetersonAndrew Greenfield · 2 companies · 1 sharedAndrew GreenfieldJEFF BLAIR · 2 companies · 1 sharedJEFF BLAIRSurindra Mitruka · 2 companies · 1 sharedSurindra MitrukaCraig Berky · 1 companies · 1 sharedCraig BerkyTimothy Blair · 1 companies · 1 sharedTimothy BlairEuphrates Vascular, Inc. · $9.7M raisedEuphrates Vascular, I…Ichor Vascular Inc. · $3.1M raisedIchor Vascular Inc.Jeffrey BlairJB
Jeffrey Blair Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Jeffrey Blair on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
TROY LONG22
Robert Mitchell19
Sean Morris17
ERIC MOESSINGER16
Mark Peterson15
THOMAS HILLMAN13
Andrew Greenfield12
Surindra Mitruka12
JEFF BLAIR12
Martin Omid Akhavan12
Tim Blair11
Timothy Blair11
Craig Berky11
Cathy Omid Matthes11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.